The outcome was well signposted by Nektar after the melanoma study read out, after which chief executive Howard Robin said the setback would lead to "substantial" changes to the company and its ...
On a conference call, Nektar chief executive Howard Robin said the outcome was "very upsetting," and investors were just as devastated, with shares in Nektar plummeting more than 60% in the wake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback